Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
Rhea-AI Summary
Agios (Nasdaq: AGIO) will report its third quarter 2025 financial results and business highlights on Thursday, October 30, 2025 at 8:00 a.m. ET.
The company will host a conference call and live webcast accessible from the Investors > Events & Presentations section of its website. A replay will be available on the company website approximately two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction – AGIO
On the day this news was published, AGIO gained 0.34%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $2.54B at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com
FAQ
When will Agios (AGIO) report Q3 2025 results?
How can investors join the Agios (AGIO) Q3 2025 earnings webcast?
Will there be a replay of the Agios (AGIO) October 30, 2025 webcast?
What time is the Agios (AGIO) conference call for third quarter 2025?
Where on the Agios website is the Q3 2025 event posted?
Will Agios (AGIO) provide quarterly business highlights during the October 30, 2025 call?
